Collegium to Acquire Corium Therapeutics in Merger

The SEC filing contains an Equity Purchase Agreement dated March 19, 2026 between Corium Therapeutics Holdings, LLC and related entities as sellers and Collegium Pharmaceutical, Inc. as buyer.

The agreement outlines purchase and sale terms, closing mechanics, purchase price adjustment provisions, escrow deposits, and milestone payments. It also includes extensive representations and warranties covering corporate organization, regulatory compliance, intellectual property, healthcare regulatory matters, product liability, and employee and benefit obligations, along with post-closing indemnification and tax-related provisions.